FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
NCT02485834 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2025-01-20
Summary
This randomized phase II trial studies how well fludeoxyglucose F-18 (FDG)/positron emission tomography (PET) directed treatment improves response in patients with stomach or gastroesophageal junction cancer that has not spread past the stomach and is not responding to the usual treatment. PET scans are a different way to take pictures of cancer and can be used to look at how much energy (such as glucose) is being used by the cancer. Using PET scans early to monitor the success of treatment may allow doctors to measure response and change treatment accordingly.
Conditions
- Adenocarcinoma of the Gastroesophageal Junction
- Gastric Adenocarcinoma
- Gastric Cancer
Interventions
- PROCEDURE
-
FDG-PET
- PROCEDURE
-
surgery
- DRUG
-
200 mg/m\^2/day IV
- DRUG
-
oral 800 mg/m\^2 BID
- DRUG
-
30 mg/m\^2 IV
- DRUG
-
50 mg/m\^2 IV
- RADIATION
-
3D-CRT
- RADIATION
-
IMRT
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Alliance for Clinical Trials in Oncology
lead OTHER
Principal Investigators
-
Manish Shah, MD · Weill Medical College of Cornell University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-12
- Primary Completion
- 2018-08-01
- Completion
- 2018-08-01
Countries
- United States
Study Locations
More Related Trials
-
Tumor Hypoxia With HX4 PET in Several Diseases
NCT02584400 ·Status: TERMINATED ·Phase: PHASE2
-
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
NCT02078843 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Molecular Imaging of Gastric Cancer Metastatic Lymph Nodes with 99mTc-3PRGD2 Probe.
NCT06435741 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
FDG-PET-CT and Biomarkers in Esophageal Cancer
NCT00833625 ·Status: COMPLETED ·Phase: NA
-
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
NCT01254591 ·Status: UNKNOWN ·Phase: NA
-
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
NCT00083083 ·Status: UNKNOWN ·Phase: PHASE2
-
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597 ·Status: UNKNOWN
-
Target-specific immunoPET Imaging of Digestive System Carcinoma
NCT06715839 ·Status: RECRUITING ·Phase: NA
-
PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy
NCT02433301 ·Status: COMPLETED
-
FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer
NCT00983697 ·Status: UNKNOWN ·Phase: NA
-
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
NCT03791905 ·Status: UNKNOWN ·Phase: PHASE2
-
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
NCT05955833 ·Status: UNKNOWN ·Phase: PHASE1
-
The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer
NCT06327386 ·Status: RECRUITING
-
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
NCT00988936 ·Status: COMPLETED ·Phase: PHASE2
-
Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
NCT05889312 ·Status: RECRUITING
-
MPDL3280A-imaging-IST-UMCG
NCT02453984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
NCT00227539 ·Status: COMPLETED ·Phase: PHASE2
-
PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
NCT04150705 ·Status: TERMINATED ·Phase: NA
-
68Ga-JH04 PET/CT in Patients With Various Types of Cancer
NCT06455735 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Predictive Value of CT-PET in Esophageal Cancer
NCT02385604 ·Status: COMPLETED
-
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
NCT00565721 ·Status: COMPLETED ·Phase: PHASE2
-
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
NCT04804371 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
In-Room PET in Proton Radiation Therapy
NCT01228448 ·Status: COMPLETED ·Phase: NA
-
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx
NCT00757549 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
NCT00230269 ·Status: COMPLETED